MedTrace Logo

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

NCT00632502 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-01-02

Study results available
· View outcomes & findings →

Summary

4-Week Safety Study in Subjects with Neutrophilic Asthma

Conditions

  • Neutrophilic Asthma

Interventions

DRUG

Navarixin

Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.

DRUG

Placebo

Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.

DRUG

Rescue medication

Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-01
Primary Completion
2009-02-01
Completion
2009-02-01

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632502 on ClinicalTrials.gov